<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1253">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04530409</url>
  </required_header>
  <id_info>
    <org_study_id>PR0012</org_study_id>
    <nct_id>NCT04530409</nct_id>
  </id_info>
  <brief_title>Timing of Corticosteroids in COVID-19</brief_title>
  <official_title>Timing of Corticosteroids in COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ClinAmygate</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ClinAmygate</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Timing of of corticosteroids administration is very important in COVID19 cases for the
      recovery and decrease the mortality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The sickest patients with COVID-19 suffer a hyperinflammatory state-a cytokine storm-that has
      features in common with a rare haematological condition called haemophagocytic
      lymphohistiocytosis. Immune suppression should help such patients. By contrast, immune
      suppression during the early phase of the viral infection might allow increased viral
      replication and aggravate the disease.

      The 3C-like proteinase on SARS-CoV-2 (nsp5) inhibits HDAC2 transport into the nucleus, and so
      impairs the way in which it mediates inflammation and cytokine responses, so activation of
      histone deacetylase by dexamethasone may directly oppose the action of SARS-CoV-2.

      Timing of of corticosteroids administration is very important in COVID19 cases for the
      recovery and decrease the mortality.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of cases that will need hospitalization</measure>
    <time_frame>one to two weeks</time_frame>
    <description>Deterioration in the clinical picture of cases that necessitate hospitalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of cases that deteriorate to acute respiratory distress syndrome</measure>
    <time_frame>one to two weeks</time_frame>
    <description>Percentage of cases whose clinical status deteriorate to acute respiratory distress syndrome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of cases with increased d-dimer</measure>
    <time_frame>two weeks</time_frame>
    <description>Percentage of cases with increased d-dimer from baseline level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery of diarrhea</measure>
    <time_frame>one to two weeks</time_frame>
    <description>Time to recovery of diarrhea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage reduction in CRP</measure>
    <time_frame>one to four weeks</time_frame>
    <description>Percentage reduction in CRP from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage reduction in LDH</measure>
    <time_frame>one to four weeks</time_frame>
    <description>Percentage reduction in LDH from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage reduction in ALT</measure>
    <time_frame>one to four weeks</time_frame>
    <description>Percentage reduction in ALT from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage reduction in Ferritin</measure>
    <time_frame>one to four weeks</time_frame>
    <description>Percentage reduction in Ferritin from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery of lymphopenia</measure>
    <time_frame>one to two weeks</time_frame>
    <description>Time to recovery of lymphopenia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery of cough</measure>
    <time_frame>one to two weeks</time_frame>
    <description>Time to recovery of cough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery of fever</measure>
    <time_frame>one to two weeks</time_frame>
    <description>Time to recovery of fever</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery of myalgia</measure>
    <time_frame>one to two weeks</time_frame>
    <description>Time to recovery of myalgia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery of anosmia</measure>
    <time_frame>one to six weeks</time_frame>
    <description>Time to recovery of anosmia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery of dyspnea</measure>
    <time_frame>one to two weeks</time_frame>
    <description>Time to recovery of dyspnea</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Covid19</condition>
  <condition>Corticosteroids</condition>
  <arm_group>
    <arm_group_label>Early CS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>early use of dexamethasone as early as the laboratory confirmation of inflammation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late CS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dexamethasone is to be used lately upon the deterioration of cases</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Early-Dexamethasone</intervention_name>
    <description>early use of dexamethasone as early as laboratory evidence of high inflammatory markers</description>
    <arm_group_label>Early CS</arm_group_label>
    <other_name>Dexamethasone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Late-Dexamethasone</intervention_name>
    <description>Use of dexamethasone on deterioration of the cases with increased severity</description>
    <arm_group_label>Late CS</arm_group_label>
    <other_name>Dexamethasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  any case with COVID-19 more than or equal to 18 years

          -  mild and moderate severity

        Exclusion Criteria:

          -  Diabetes

          -  Any contra-indication for the interventional drug

          -  Mentally disabled cases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emad R Issak</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assalam Clinics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emad R Issak, MD</last_name>
    <phone>01272228989</phone>
    <email>dr.emad.r.h.issak@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asalam</name>
      <address>
        <city>Maadi</city>
        <state>Cairo</state>
        <zip>11433</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emad R Issak, MD</last_name>
      <phone>01272228989</phone>
      <email>dr.emad.r.h.issak@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Spoorenberg SM, Deneer VH, Grutters JC, Pulles AE, Voorn GP, Rijkers GT, Bos WJ, van de Garde EM. Pharmacokinetics of oral vs. intravenous dexamethasone in patients hospitalized with community-acquired pneumonia. Br J Clin Pharmacol. 2014 Jul;78(1):78-83. doi: 10.1111/bcp.12295.</citation>
    <PMID>24400953</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2020</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>ClinAmygate</investigator_affiliation>
    <investigator_full_name>Emad Roushdy</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>COVID19</keyword>
  <keyword>dexamethazone</keyword>
  <keyword>methylpredisolone</keyword>
  <keyword>early recovery</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

